# Hospira, now a wholly owned subsidiary of Pfizer

Organization · id `cardio:org-hospira-now-a-wholly-owned-subsidiary-of-pfizer` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Hospira%2C+now+a+wholly+owned+subsidiary+of+Pfizer>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Hospira, now a wholly owned subsidiary of Pfizer
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa \[Epogen\] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (`cardio:ct-nct01473407`)
- Sponsors: A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa \[Epogen\] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (`cardio:ct-nct01473420`)
- Sponsors: A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis (`cardio:ct-nct02504294`)

## Provenance

Content hash: 5b5db0d93a0569b97bd737519d7f7b72014e28c709a1390a8351144d59b7dfa6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
